CEO Corner

Our business is your business!

A study published by the Norwegian Institute of Public Health shows that among all health care workers, ambulance personnel were most infected by the coronavirus, with an infection rate of 1,83 percent. Today, with almost 270 hospitalized around Norway, the fear of EMS services collapsing at coronavirus hotspots is rising. Employees are worried not only for their health and safety but for the safety of their families to which they must return after every shift.

When infection appears among employees it affects the healthcare services of the entire population resulting in delays and interruptions in providing care and treatments. Keeping employees safe and protected should be a top priority at this point when the third wave continues to strike.

At EpiGuard we take our role in the pandemic seriously, and we are convinced that the usage of single-patient isolation units, which are proven to be the most helpful tool in infectious transport, will lead to fewer infections among the healthcare workers.

Safe patient transport is very important when hospitals get overcrowded. One of many examples is Germany which offered its neighbouring countries to send the patients to German hospitals that had spare capacity. Another example is Oslo, where the hospitals are struggling with full intensive care capacities. Ill covid patients on respirators have been transported in an intensive care ambulance between the hospitals in Helse Sør-Øst, with many more waiting to be transported.

With 27 EpiShuttles now in operation, Norway is ready to help the healthcare workers to perform their daily jobs without getting infected.

EpiGuard has a lot to offer, and we have come along way, but we are going further!

We have good fundamentals in place for growth and a solid commercial foothold. Our business is allowing the development of life-saving medical equipment and is a very good indicator that EpiShuttle is performing its mission – keeping everyone safe from infection.

Sounds interesting?

Subscribe to our newsletter and be the first to know about Ellens’ future topics!

Subscribe

Copyright 2019 @ EpiGuard